Proposed Study to Investigate Intranasal Oxytocin's Impact on Empathy in Schizophrenia and Healthy Controls

Schizophrenia is characterized by significant social dysfunction, often linked to impaired empathy and specific deficits in effective Theory of Mind (ToM). These impairments severely hinder social integration. Oxytocin, a crucial neuromodulator, plays an indispensable role in various complex prosocial behaviors, including maternal care, attachment, and trust. Given its known involvement in social cognition, understanding oxytocin's potential to modulate empathy mechanisms could offer novel therapeutic avenues for social deficits in schizophrenia.

This abstract describes a proposed study designed to investigate the influence of a single dose of intranasal Oxytocin on empathy. The study plans to assess two primary mechanisms of empathy: mentalizing (Theory of Mind) and Simulation. Participants will include both healthy individuals and those diagnosed with schizophrenia. The abstract does not specify dosage, frequency, duration, sample size, or control arm details, as it outlines the study's intent rather than its execution.

This abstract describes a proposed study and therefore presents no experimental findings or results. The research aims to explore the effects of intranasal oxytocin on empathic abilities, specifically mentalizing (Theory of Mind) and Simulation, in both healthy individuals and those with schizophrenia. However, the actual data collection and analysis have not yet occurred or are not reported within this abstract. Consequently, no specific numerical outcomes, statistical significances, observed changes in cognitive or affective empathy components, or comparisons between groups are available from this preliminary outline. The abstract focuses solely on the rationale and design objectives of the planned investigation.